We are pleased to present below all posts archived in 'December, 2014'. If you still can't find what you are looking for, try using the search box.
- IRIDICA has the potential to change how pathogens that cause serious infections, such as sepsis and pneumonia, are detected and identified
- May provide doctors with information needed to start treating those who are critically ill with appropriate therapies sooner
- May help reduce the use of broad-spectrum antibiotics, a leading cause of antibiotic resistance
Read the rest of entry »
Bootle-based Mast Group has won the Medical Engineers Outstanding Achievement Award at the Medilink North West Awards.
The new assay is certified for both diagnosis and viral load monitoring on the Panther system
Bedford, Mass., Dec. 1, 2014 -- Hologic, Inc. (NASDAQ: HOLX), today announced CE mark certification for its new Aptima HIV-1 Quant Dx assay for use on the Company’s Panther system. The Aptima HIV-1 Quant Dx assay, employing Hologic proprietary real-time transcription-mediated amplification (Real-time TMA) technology, is the first HIV viral load assay with a dual claim for both diagnosis and treatment monitoring. This milestone marks Hologic’s entry into the viral load market.
Who are the BIVDA Members
Member Press Releases
Point of Care Directory
News, Policy and Media
BIVDA Press Releases